Thrombosis
Conditions
Brief summary
The primary aim of this study is to evaluate safety and tolerability data when SRSD107 is administered as single SC injections to healthy participants. This information, along with PK/PD data, will help establish the appropriate doses and dosing regimen for future studies in patients.
Detailed description
SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA). The antisense strand is specifically designed to recognize and cleave human factor XI (FXI) messenger ribonucleic acid (mRNA) which reduces FXI protein. FXI protein reduction may prevent thromboembolic events without increasing the risk of bleeding. This study will be a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study conducted in two parts. A total of 40 participants will be studied in 5 groups (Groups A1 to A5), each group consisting of 8 participants. In each group, 6 participants will receive SRSD107 and 2 will receive a placebo.
Interventions
DRUGSRSD107
SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).
DRUGPlacebo
Sodium chloride
Sponsors
Sirius Therapeutics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Body mass index between 18.0 and 32.0 kg/m2, inclusive. * In good health, based on no clinically significant findings from medical history, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations. * Activated partial thromboplastin time and PT within the normal range. * Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception. * Able to understand and willing to sign an ICF and to abide by the study restrictions.
Exclusion criteria
* Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee). * History or evidence of any abnormal bleeding or coagulation disorder; or evidence of coagulopathy, prolonged or unexplained, clinically significant bleeding, or frequent unexplained bruising or thrombus formation; or a history of spontaneous bleeding. * Evidence of an active or suspected cancer, or a history of malignancy, within 5 years prior to screening. Nonmelanoma skin cancer, curatively treated localized prostate cancer, or other carcinoma in situ are not exclusionary, providing that they did not require systemic therapy and are considered cured. * Acute of febrile illness within 7 days prior to dose administration or evidence of active infection. * Any major surgery within 3 months prior to screening or plan to have any surgery during the study. * History of clinically significant hypersensitivity, intolerance, or allergy to any drug compound, oligonucleotide, GalNAc, food, or other substance, as determined by the investigator (or designee). * Confirmed systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. * QT interval corrected for heart rate using Fridericia's method (QTcF) \>450 ms in males or \>470 ms in females confirmed by repeat measurement. * White blood cell count \<3.5 × 109/L, platelets \<100 × 109/L, or hemoglobin below the lower limit of normal. * Alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, alkaline phosphatase, or total bilirubin \>1.5 × the upper limit of normal (ULN). * Estimated glomerular filtration rate \<80 mL/min/1.73m2, as calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration equation. * Positive hepatitis panel and/or positive human immunodeficiency virus test. * Positive pregnancy test at screening or check in. * Receipt of blood products within 2 months prior to check in. * Loss of \>500 mL whole blood or donation of blood products within 1 month prior to screening. * History of intolerance to SC injections, or scarring (eg, from surgical procedures or burns) in areas when SC dose administration may occur. * Participants who, in the opinion of the investigator (or designee), should not participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of adverse events (AEs) | up to 168 days post last dose | An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. |
| Proportion of Serious Adverse Events (SAEs) | up to 168 days post last dose | A serious AE (SAE) is defined as any untoward medical occurrence that at any dose either: * results in death * is life threatening * requires inpatient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity (disability is defined as a substantial disruption of a person's ability to conduct normal life functions) * results in a congenital anomaly/birth defect * results in an important medical event (see below). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| t1/2 | Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31 | Plasma half-life |
| AUC | Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31 | Area under the plasma concentration-time curve from 0 to infinity |
| Cmax | Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31 | Maximum observed plasma concentration |
| Effect of SRSD107 on circulating FXI Levels | up to 168 days post last dose | Determination of % Lowering of FXI to Baseline FXI Level |
| Effect of SRSD107 on coagulation | up to 168 days post last dose | Determination of % APTT to baseline APTT |
| CL/F | Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31 | Apparent total clearance |
| tmax | Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31 | Time to maximum plasma concentration |
Countries
Australia
Outcome results
None listed